rs767128094
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000198.4(HSD3B2):c.1064G>A(p.Trp355Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000205 in 1,461,768 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 31)
Exomes 𝑓: 0.0000021 ( 0 hom. )
Consequence
HSD3B2
NM_000198.4 stop_gained
NM_000198.4 stop_gained
Scores
5
1
1
Clinical Significance
Conservation
PhyloP100: 9.15
Genes affected
HSD3B2 (HGNC:5218): (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2) The protein encoded by this gene is a bifunctional enzyme that catalyzes the oxidative conversion of delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. It plays a crucial role in the biosynthesis of all classes of hormonal steroids. This gene is predominantly expressed in the adrenals and the gonads. Mutations in this gene are associated with 3-beta-hydroxysteroid dehydrogenase, type II, deficiency. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Oct 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
?
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.0492 CDS is truncated, and there are 2 pathogenic variants in the truncated region.
PM2
?
Very rare variant in population databases, with high coverage;
PP5
?
Variant 1-119422565-G-A is Pathogenic according to our data. Variant chr1-119422565-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 517183.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
HSD3B2 | NM_000198.4 | c.1064G>A | p.Trp355Ter | stop_gained | 4/4 | ENST00000369416.4 | |
HSD3B2 | NM_001166120.2 | c.1064G>A | p.Trp355Ter | stop_gained | 4/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
HSD3B2 | ENST00000369416.4 | c.1064G>A | p.Trp355Ter | stop_gained | 4/4 | 1 | NM_000198.4 | P1 | |
HSD3B2 | ENST00000543831.5 | c.1064G>A | p.Trp355Ter | stop_gained | 4/4 | 3 | P1 |
Frequencies
GnomAD3 genomes ? Cov.: 31
GnomAD3 genomes
?
Cov.:
31
GnomAD3 exomes AF: 0.00000797 AC: 2AN: 250916Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135614
GnomAD3 exomes
AF:
AC:
2
AN:
250916
Hom.:
AF XY:
AC XY:
0
AN XY:
135614
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461768Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 727188
GnomAD4 exome
AF:
AC:
3
AN:
1461768
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
727188
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? Cov.: 31
GnomAD4 genome
?
Cov.:
31
ExAC
?
AF:
AC:
1
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
3 beta-Hydroxysteroid dehydrogenase deficiency Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 19, 2016 | The p.Trp355X variant in HSD3B2 has been reported in a homozygous individual wit h clinical features of 3-beta (?)-hydroxysteroid dehydrogenase (HSD) deficiency (Welzel 2008). The p.Trp355X variant has been identified in 1/6498 of South Asia n chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstit ute.org; dbSNP rs767128094). This nonsense variant leads to a premature terminat ion codon at position 355, which is predicted to lead to a truncated or absent p rotein. Biallelic loss of function of the HSD3B2 gene has been associated with H SD deficiency. In vitro studies provide evidence that this variant leads to a tr uncated protein which impacts protein function (Welzel 2008). However, these typ es of assays may not accurately represent biological function. In summary, alth ough additional studies are required to fully establish a null effect on the pro tein, the p.Trp355X variant in HSD3B2 is likely pathogenic for 3-beta (?)-hydrox ysteroid dehydrogenase (HSD) deficiency in an autosomal recessive manner based u pon its predicted impact on protein function. - |
Congenital adrenal hyperplasia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 26, 2022 | Variant summary: HSD3B2 c.1064G>A (p.Trp355X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been in association with Adrenal hyperplasia and 3 beta-hydroxysteroid dehydrogenase deficiency in HGMD. The variant allele was found at a frequency of 8e-06 in 250916 control chromosomes. c.1064G>A has been reported in the literature in an individual affected with Congenital Adrenal Hyperplasia (Welzel_2008). These data indicate that the variant is likely to be associated with disease. One publication reports experimental evidence evaluating an impact on protein expression and enzymatic activity, resulting in <10% of normal activity and no or very little protein expression in the absence of a proteasome inhibitor (Welzel_2008). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, classifying the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
D;D
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at